Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) from a sell rating to a hold rating in a research note issued to investors on Saturday.
According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
A number of other equities analysts have also recently commented on TTPH. HC Wainwright started coverage on Tetraphase Pharmaceuticals in a report on Tuesday, July 11th. They issued a buy rating and a $15.00 target price for the company. Stifel Nicolaus upgraded Tetraphase Pharmaceuticals from a hold rating to a buy rating and lifted their target price for the stock from $8.00 to $15.00 in a report on Wednesday, July 26th. BMO Capital Markets reiterated an outperform rating and issued a $13.00 target price (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a report on Wednesday, July 26th. Needham & Company LLC reiterated a hold rating on shares of Tetraphase Pharmaceuticals in a report on Thursday, July 27th. Finally, BidaskClub cut Tetraphase Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, August 10th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $12.96.
Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at 6.01 on Friday. The firm has a 50-day moving average price of $6.76 and a 200 day moving average price of $7.06. The stock’s market cap is $306.83 million. Tetraphase Pharmaceuticals has a 52 week low of $3.11 and a 52 week high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.07). The firm had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $1.54 million. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The business’s quarterly revenue was up 28.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.47) EPS. On average, analysts forecast that Tetraphase Pharmaceuticals will post ($2.91) EPS for the current fiscal year.
In related news, insider Jacques Dumas sold 17,500 shares of the business’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $6.00, for a total transaction of $105,000.00. Following the completion of the transaction, the insider now owns 17,500 shares in the company, valued at approximately $105,000. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.50% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Schwab Charles Investment Management Inc. raised its position in Tetraphase Pharmaceuticals by 6.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 128,807 shares of the biopharmaceutical company’s stock valued at $1,184,000 after purchasing an additional 7,866 shares in the last quarter. Vanguard Group Inc. raised its position in Tetraphase Pharmaceuticals by 16.4% during the 1st quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock valued at $15,061,000 after purchasing an additional 230,420 shares in the last quarter. Bank of New York Mellon Corp raised its position in Tetraphase Pharmaceuticals by 3.4% during the 1st quarter. Bank of New York Mellon Corp now owns 187,897 shares of the biopharmaceutical company’s stock valued at $1,726,000 after purchasing an additional 6,114 shares in the last quarter. Geode Capital Management LLC raised its position in Tetraphase Pharmaceuticals by 17.0% during the 1st quarter. Geode Capital Management LLC now owns 313,390 shares of the biopharmaceutical company’s stock valued at $2,880,000 after purchasing an additional 45,554 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Tetraphase Pharmaceuticals by 180.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 634,300 shares of the biopharmaceutical company’s stock valued at $5,829,000 after purchasing an additional 408,078 shares in the last quarter. 40.92% of the stock is owned by institutional investors and hedge funds.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Tetraphase Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tetraphase Pharmaceuticals Inc. and related companies.